Could Helus Pharma’s New CEO Reframe Cybin’s (HELP) Path From Clinical Trials To Commercial Scale?

• On August 3, 2026, Helus Pharma appointed Michael Halstead as Chief Executive Officer, bringing 25 years of biopharma experience and a record of leading major drug launches, large-scale integrations and multi billion-dollar M&A transactions.
• Halstead’s history of guiding companies from clinical development to full commercial operations may signal a shift in how Helus Pharma approaches growth, partnerships and capital allocation.
• We’ll now explore how bringing in a CEO with extensive commercialization and M&A experience could influence Cybin’s existing investment narrative.

Capitalize on the AI infrastructure supercycle with our selection of the 56 best 'picks and shovels' of the AI gold rush converting record-breaking demand into massive cash flow.

Cybin Investment Narrative Recap

To own Cybin, you need to believe that its late stage psychedelic programs for depression and anxiety can eventually translate into real world clinic adoption and future cash flows, despite today’s zero revenue and US$148.0 million annual net loss. Halstead’s arrival at Helus Pharma does not change the near term focus on Phase 3 HLP003 data and clinic uptake, but it may affect how the company manages partnerships and future capital needs.

The most relevant recent announcement here is the completion of enrollment in the APPROACH Phase 3 trial for HLP003, with topline data guided for Q4 2026. That milestone keeps the primary clinical catalyst clearly defined, while Halstead’s commercialization and M&A track record frames how Helus might prepare if results are positive, potentially influencing how any future revenue stream from HLP003 is supported and scaled.

Yet behind the excitement around Phase 3 data and a high profile CEO hire, investors should be aware that...

Read the full narrative on Cybin (it's free!)

Cybin’s narrative projects $211.5 million in revenue and $45.3 million in earnings by 2029. This implies an earnings increase of about $193 million from -$148.0 million today.

Uncover how Cybin's forecasts yield a $37.57 fair value, a 257% upside to its current price.

Exploring Other Perspectives

Before Halstead’s appointment, the most optimistic analysts were already modeling about US$565.4 million in 2029 revenue and US$66.6 million in earnings, so if you agreed with those forecasts, you were effectively embracing a far more optimistic story than consensus. Now, with a CEO whose track record speaks to commercialization and large M&A, it is worth asking whether those bullish expectations still feel aggressive, too cautious, or somewhere in between as the Cybin thesis continues to evolve.

Explore 7 other fair value estimates on Cybin - why the stock might be a potential multi-bagger!

Decide For Yourself

Don't just follow the ticker - dig into the data and build a conviction that's truly your own.

• A great starting point for your Cybin research is our analysis highlighting 1 key reward and 5 important warning signs that could impact your investment decision.
• Our free Cybin research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Cybin's overall financial health at a glance.

Searching For A Fresh Perspective?

Every day counts. These free picks are already gaining attention. See them before the crowd does:

• Invest in the nuclear renaissance through our list of 89 elite nuclear energy infrastructure plays powering the global AI revolution.
• AI is about to change healthcare. These 42 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.
• This technology could replace computers: discover 26 stocks that are working to make quantum computing a reality.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com